# Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
**Date:** 2025-10-29 03:00:00
**Company:** Biogen Inc.
**Ticker:** BIIB
**Source URL:** https://www.businesswire.com/news/home/20251029326593/en/Samsung-Bioepis-to-Commercialize-BYOOVIZ%C2%AE-ranibizumab-in-Europe-from-January-2026/
---
Oct 29, 2025 3:00 AM Eastern Daylight Time
# **Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026**
Share
* * *
- _Samsung Bioepis will assume full commercial responsibility for BYOOVIZ_ ® _(ranibizumab) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026_
- _BYOOVIZ, approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe, has been commercially available in several European countries since March 2023_
INCHEON, Korea--( [BUSINESS WIRE](https://www.businesswire.com/))--Samsung Bioepis Co., Ltd. announced today that the compa...
# Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026
**Date:** 2025-10-29 03:00:00
**Company:** Biogen Inc.
**Ticker:** BIIB
**Source URL:** https://www.businesswire.com/news/home/20251029326593/en/Samsung-Bioepis-to-Commercialize-BYOOVIZ%C2%AE-ranibizumab-in-Europe-from-January-2026/
---
Oct 29, 2025 3:00 AM Eastern Daylight Time
# **Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 2026**
Share
* * *
- _Samsung Bioepis will assume full commercial responsibility for BYOOVIZ_ ® _(ranibizumab) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026_
- _BYOOVIZ, approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe, has been commercially available in several European countries since March 2023_
INCHEON, Korea--( [BUSINESS WIRE](https://www.businesswire.com/))--Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026.
> We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe. We will work closely with Biogen to ensure a seamless transition and the continued delivery of services to our customers and patients in Europe.
>
> Share
“We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe. We will work closely with Biogen to ensure a seamless transition and the continued delivery of services to our customers and patients in Europe,” said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial, at Samsung Bioepis. “Samsung Bioepis will continue to broaden our reach to patients across Europe by reinforcing our leadership and expertise in biosimilars.”
BYOOVIZ (ranibizumab) was approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). BYOOVIZ became commercially available in several countries within Europe from March 2023. OPUVIZ (aflibercept) was approved by the EC in November 2024 and by the Medicines and Healthcare products Regulatory Agency (MHRA) in April 2025 for the treatment of patients with Wet AMD, Visual Impairment due to Macular Oedema Secondary to RVO, Visual Impairment due to Diabetic Macular Edema (DME), and Visual Impairment due to mCNV. OPUVIZ will not be launched until after the lapse or revocation of relevant patent(s) for the reference biologic Eylea that also covers OPUVIZ in Europe.
**About Samsung Bioepis Co., Ltd.**
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, and endocrinology. For more information, please visit: [www.samsungbioepis.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.samsungbioepis.com&esheet=54347270&newsitemid=20251029326593&lan=en-US&anchor=www.samsungbioepis.com&index=1&md5=511e40f707e08ad899ef96d36dd02235) and follow us on social media – [LinkedIn](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsamsungbioepis&esheet=54347270&newsitemid=20251029326593&lan=en-US&anchor=LinkedIn&index=2&md5=c46c1530df1f1e0874e07f6ce8e38991), [X](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fx.com%2Fsamsungbioepis&esheet=54347270&newsitemid=20251029326593&lan=en-US&anchor=X&index=3&md5=2e5d5cad21882fe366d25b6ae94ccdde).
| | |
| --- | --- |
| i | Lucentis is a trademark of Genentech, Inc. |
| ii | Eylea is a trademark of Bayer AG |
Expand
## Contacts
**MEDIA CONTACT**
Anna Nayun Kim, [nayun86.kim@samsung.com](mailto:nayun86.kim@samsung.com)
Yoon Kim, [yoon1.kim@samsung.com](mailto:nayun86.kim@samsung.com)
Industry:
- [Health](https://www.businesswire.com/newsroom?industry=1000088)
- [Diabetes](https://www.businesswire.com/newsroom?industry=1050069)
- [Research](https://www.businesswire.com/newsroom?industry=1000159)
- [Science](https://www.businesswire.com/newsroom?industry=1050101)
- [Pharmaceutical](https://www.businesswire.com/newsroom?industry=1000146)
- [Optical](https://www.businesswire.com/newsroom?industry=1000124)
- [Biotechnology](https://www.businesswire.com/newsroom?industry=1000039)
[](https://www.samsungbioepis.com/en/index.do)
### Samsung Bioepis Co., Ltd.
* * *
Release Versions
[English](https://www.businesswire.com/news/home/20251029326593/en/Samsung-Bioepis-to-Commercialize-BYOOVIZ-ranibizumab-in-Europe-from-January-2026) [Spanish (Summary)](https://www.businesswire.com/news/home/20251029383154/es) [German](https://www.businesswire.com/news/home/20251029306449/de) [French](https://www.businesswire.com/news/home/20251029928276/fr) [Italian (Summary)](https://www.businesswire.com/news/home/20251029194720/it) [Dutch (Summary)](https://www.businesswire.com/news/home/20251029223057/nl)
Hashtags
[#BYOOVIZ](https://x.com/hashtag/BYOOVIZ?src=hash)
[#Biogen](https://x.com/hashtag/Biogen?src=hash)
[#Biosimilar](https://x.com/hashtag/Biosimilar?src=hash)
[#Biosimilars](https://x.com/hashtag/Biosimilars?src=hash)
[#InnovatingAccess](https://x.com/hashtag/InnovatingAccess?src=hash)
[#PassionforHealth](https://x.com/hashtag/PassionforHealth?src=hash)
[#SamsungBioepis](https://x.com/hashtag/SamsungBioepis?src=hash)
[#ranibizumab](https://x.com/hashtag/ranibizumab?src=hash)
* * *
### Contacts
**MEDIA CONTACT**
Anna Nayun Kim, [nayun86.kim@samsung.com](mailto:nayun86.kim@samsung.com)
Yoon Kim, [yoon1.kim@samsung.com](mailto:nayun86.kim@samsung.com)
Social Media Profiles
[Samsung Bioepis on LinkedIn](https://www.linkedin.com/company/samsungbioepis)
[Samsung Bioepis on X](https://x.com/samsungBioepis)
More News From Samsung Bioepis Co., Ltd.
Get RSS Feed
[**Samsung Bioepis Initiates Phase 1 Clinical Trial for SBE303, Nectin-4 Targeting Antibody-Drug Conjugate (ADC) Candidate**](https://www.businesswire.com/news/home/20260414313544/en/Samsung-Bioepis-Initiates-Phase-1-Clinical-Trial-for-SBE303-Nectin-4-Targeting-Antibody-Drug-Conjugate-ADC-Candidate)
INCHEON, Korea--( [BUSINESS WIRE](https://www.businesswire.com/))--Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.1 The Phase 1 clinical trial for SBE303 is an open‑label, multi-center, first‑in‑human trial to evaluate the safety, tolerability an...
[**Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates**](https://www.businesswire.com/news/home/20260318826412/en/Samsung-Bioepis-Enters-into-Partnership-Agreement-with-Sandoz-for-Up-to-Five-Next-Generation-Biosimilar-Candidates)
INCHEON, Korea--( [BUSINESS WIRE](https://www.businesswire.com/))--Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab). The other terms of the agreement remain confidential. Under the terms of the agreement, Samsung Bioepis will be responsible for development, regulatory registra...
[**Samsung Bioepis and Epis NexLab Sign Research Collaboration and License Agreement with G2GBIO to Develop Novel Assets Including Long-acting Semaglutide**](https://www.businesswire.com/news/home/20260316253695/en/Samsung-Bioepis-and-Epis-NexLab-Sign-Research-Collaboration-and-License-Agreement-with-G2GBIO-to-Develop-Novel-Assets-Including-Long-acting-Semaglutide)
INCHEON, Korea--( [BUSINESS WIRE](https://www.businesswire.com/))--Samsung Bioepis Co., Ltd. and Epis NexLab Co., Ltd., a sister company to Samsung Bioepis under Samsung Epis Holdings (KRX: 0126Z0), today announced a research collaboration and license agreement with G2GBIO, a company specializing in the development of sustained-release formulations, to develop novel assets based on G2GBIO’s proprietary microsphere technology. Under the agreement, Samsung Bioepis will be given a full license right for the novel long-acting semag...
[Back to Newsroom](https://www.businesswire.com/newsroom)
[](https://www.samsungbioepis.com/en/index.do)
### Samsung Bioepis Co., Ltd.
* * *
Release Versions
[English](https://www.businesswire.com/news/home/20251029326593/en/Samsung-Bioepis-to-Commercialize-BYOOVIZ-ranibizumab-in-Europe-from-January-2026) [Spanish (Summary)](https://www.businesswire.com/news/home/20251029383154/es) [German](https://www.businesswire.com/news/home/20251029306449/de) [French](https://www.businesswire.com/news/home/20251029928276/fr) [Italian (Summary)](https://www.businesswire.com/news/home/20251029194720/it) [Dutch (Summary)](https://www.businesswire.com/news/home/20251029223057/nl)
Hashtags
[#BYOOVIZ](https://x.com/hashtag/BYOOVIZ?src=hash)
[#Biogen](https://x.com/hashtag/Biogen?src=hash)
[#Biosimilar](https://x.com/hashtag/Biosimilar?src=hash)
[#Biosimilars](https://x.com/hashtag/Biosimilars?src=hash)
[#InnovatingAccess](https://x.com/hashtag/InnovatingAccess?src=hash)
[#PassionforHealth](https://x.com/hashtag/PassionforHealth?src=hash)
[#SamsungBioepis](https://x.com/hashtag/SamsungBioepis?src=hash)
[#ranibizumab](https://x.com/hashtag/ranibizumab?src=hash)
* * *
### Contacts
**MEDIA CONTACT**
Anna Nayun Kim, [nayun86.kim@samsung.com](mailto:nayun86.kim@samsung.com)
Yoon Kim, [yoon1.kim@samsung.com](mailto:nayun86.kim@samsung.com)
Social Media Profiles
[Samsung Bioepis on LinkedIn](https://www.linkedin.com/company/samsungbioepis)
[Samsung Bioepis on X](https://x.com/samsungBioepis)
## Wish your news had this kind of reach?
[Sign Up](https://www.businesswire.com/sign-up/account) [Learn About Business Wire](https://www.businesswire.com/why-business-wire)